Rosetta Genomics now Processing Fine-Needle Aspirate Cell Block Samples for Lung Cancer Subclassification
News Apr 07, 2010
Rosetta Genomics, Ltd. has announced that starting April 1, 2010 physicians are able to send FNA cell block samples to Rosetta Genomics' CLIA-certified and CAP-accredited laboratory in Philadelphia for analysis using Rosetta's miRview squamous test. FNA is a less invasive method to obtain tumor cells compared with tumor resections or biopsies. This breakthrough will enable patients and physicians to benefit from an accurate diagnostic assay without having to undergo a more invasive procedure.
miRview squamous is a molecular diagnostic test that measures the expression level of a single microRNA to accurately differentiate squamous from non-squamous NSCLC. The test offers patients and physicians a highly accurate diagnostic tool that produces standardized and reproducible results.
"Enabling physicians to subclassify NSCLC tumors with miRview squamous based on FNA cell blocks, without the need for more invasive procedures, brings significant value to lung cancer patient management," noted Dr. Tina Edmonston, Director of Rosetta Genomics' CLIA-certified laboratory. "As pathologists, we are often faced with challenges especially when trying to subclassify poorly differentiated NSCLCs. However, correct subclassification is crucial to determine the treatment of the patient. We believe this new capability will help physicians better address this issue."
"This improvement is an excellent example of how by adapting our proprietary miRNA-based technologies to be used on FNA cell block specimens, our highly accurate miRview squamous assay can be made available to more patients suffering from lung cancer," stated Ken Berlin, President and CEO of Rosetta Genomics.
In a recently published study in Clinical Cancer Research, Johns Hopkins University researchers demonstrated that miRview squamous correctly subclassified 95% of FNA cell block specimens and small biopsies originally diagnosed as poorly differentiated NSCLC into squamous and non-squamous cell carcinoma.
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE